Fridays vs OrderlyMeds (2026): prices, structure, verdict

On tirzepatide, OrderlyMeds↗ is cheaper: $299 versus $359 a month all-in — a $60 monthly gap, $720 across a year of maintenance dosing.

Updated 2026-08-10 · figures captured 2026-08-09 · how we verify

On semaglutide, OrderlyMeds is cheaper: $149 versus $175 a month all-in — a $26 monthly gap, $312 across a year of maintenance dosing.

§ Side by side

§ Each record, read aloud

The two records, condensed

Fridays: the record, condensed

Fridays’s tirzepatide program bills $359 a month once every mandatory fee is counted, measured at the 10 mg maintenance basis. It is a flat structure: 2.5 → 5 → 7.5 → 10 mg (12.5 and 15 mg available) all bill identically. In a market where most low advertised prices quietly belong to the starter dose, a flat figure is the difference between a quote and a teaser.

There is no membership line. $359 is the billed total — consultation and clinical review are inside it, and no platform fee recurs beside it, which removes the most common way advertised GLP-1 prices understate billed ones.

Context for that figure: it ranks #13 of 17 in the verified tirzepatide index — $144/month above the floor (NexLife↗, $215) — and sits $90 under the brand benchmark (Zepbound (LillyDirect↗), $449 at maintenance). Annualized, a monthly-billed year here runs $4,308.

Fridays’s semaglutide program bills $175 a month once every mandatory fee is counted, measured at the 2.4 mg maintenance basis. The price is dose-flat: the standard titration ladder (0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg) is financially invisible here, because the top rung bills exactly what the bottom rung billed. That converts the advertised number from a floor into a ceiling — the strongest single structural feature a program in this category can have.

The absence worth noticing: no mandatory membership. Across this index memberships run $25–$145 a month and hide outside headline prices; here the headline is the bill.

To place the number: #7 of 20 verified programs, with the floor $42/month below at Oak Longevity ($133); the approved-product yardstick (Wegovy (NovoCare↗)) sits at $349, so the compounded case here is worth $174 a month. A year at this figure: $2,100 monthly-billed.

Operationally at Fridays: shipping included; commitment annual plan for lowest rate; cancellation not published; pharmacy not publicly named — ask in writing before paying; states: not published; evidence third-party reported, captured 2026-08-05. The full record with source and archive links: the Fridays page · visit Fridays ↗

OrderlyMeds: the record, condensed

Start with the load-bearing figure: $299 a month, all-in, is what OrderlyMeds charges for tirzepatide at the 10 mg basis. It is a flat structure: 2.5 → 5 → 7.5 → 10 mg (12.5 and 15 mg available) all bill identically. In a market where most low advertised prices quietly belong to the starter dose, a flat figure is the difference between a quote and a teaser.

There is no membership line. $299 is the billed total — consultation and clinical review are inside it, and no platform fee recurs beside it, which removes the most common way advertised GLP-1 prices understate billed ones.

Context for that figure: it ranks #8 of 17 in the verified tirzepatide index — $84/month above the floor (NexLife, $215) — and sits $150 under the brand benchmark (Zepbound (LillyDirect), $449 at maintenance). Annualized, a monthly-billed year here runs $3,588.

Start with the load-bearing figure: $149 a month, all-in, is what OrderlyMeds charges for semaglutide at the 2.4 mg basis. Because pricing is flat across the ladder (0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg), a dose increase at OrderlyMeds is a clinical event and not a billing one. Whatever your prescriber decides, the invoice does not move, which makes this one of the few programs whose headline figure you can actually plan a year around.

Nothing recurs on top: no membership, no platform fee, no “provider access” line. The $149 is the whole subscription, which makes OrderlyMeds unusually easy to compare and unusually easy to leave.

To place the number: #4 of 20 verified programs, with the floor $16/month below at Oak Longevity ($133); the approved-product yardstick (Wegovy (NovoCare)) sits at $349, so the compounded case here is worth $200 a month. A year at this figure: $1,788 monthly-billed.

Operationally at OrderlyMeds: shipping included; commitment none stated; cancellation not published; pharmacy not publicly named — ask in writing before paying; states: not published; evidence no public price, captured 2026-08-05. The full record with source and archive links: the OrderlyMeds page · visit OrderlyMeds ↗

Tirzepatide: the duel in full

The tirzepatide arithmetic between these two is short: $299 (OrderlyMeds) against $359 (Fridays). $60 a month sounds survivable; $720 a year is a decision.

Both figures are dose-flat, which is the cleanest possible comparison: two ceilings, no titration surprises on either side, and the $60 gap is exactly what it appears to be.

Semaglutide: the duel in full

Put the two semaglutide figures side by side and hold them there: OrderlyMeds at $149, Fridays at $175 — a $26 monthly spread that compounds to $312 over a maintenance year and $624 over two.

Both figures are dose-flat, which is the cleanest possible comparison: two ceilings, no titration surprises on either side, and the $26 gap is exactly what it appears to be.

Translate the $60/month spread into medication: $720 a year equals roughly 2.4 months of therapy at the cheaper program’s rate. That is the honest unit for gaps in this market — months of treatment, not abstract dollars — and it is why small-looking monthly differences decide long courses.

On best published rate — the lower of each program’s month-to-month price and its labeled 12-month-plan rate, which is the sort most price roundups quietly run — the duel reads: Fridays $359/mo month-to-month versus OrderlyMeds $299/mo month-to-month. Same winner on both bases — OrderlyMeds leads whether you compare month-to-month prices or committed-plan rates, which makes this one of the cleaner verdicts in the index. Prepaid rates are upfront commitments with refund terms to verify before they count.

§ The clock, run forward

Three, six, twelve, twenty-four months — best path each way

3 months: Fridays $1,077 monthly; OrderlyMeds $897 monthly — best path favors OrderlyMeds by $180. 6 months: Fridays $2,154 monthly; OrderlyMeds $1,794 monthly — best path favors OrderlyMeds by $360. 12 months: Fridays $4,308 monthly; OrderlyMeds $3,588 monthly — best path favors OrderlyMeds by $720. 24 months: Fridays $8,616 monthly; OrderlyMeds $7,176 monthly — best path favors OrderlyMeds by $1,440.

Prepaid paths above are billed upfront and assume the published rate holds (the 24-month figures extend the 12-month rate, an assumption worth naming). The honest reading: over short horizons the monthly gap decides; over long horizons the prepaid ladders and structural traps (dose tiers, memberships) take over — which is exactly the split the verdict section below scores.

The same clock, on semaglutide

3 mo: Fridays $525 vs OrderlyMeds $447 — $78 to OrderlyMeds. 6 mo: Fridays $1,050 vs OrderlyMeds $894 — $156 to OrderlyMeds. 12 mo: Fridays $2,100 vs OrderlyMeds $1,788 — $312 to OrderlyMeds. 24 mo: Fridays $4,200 vs OrderlyMeds $3,576 — $624 to OrderlyMeds.

Same rules as above: prepaid figures are upfront commitments, and the 24-month lines extend the 12-month rate as a stated assumption. Where the two molecules crown different winners between these two programs, that split is itself the finding — molecule choice and provider choice are separate decisions.

§ Structure vs structure

Everything besides the price

Coverage: Fridays publishes “not published”; OrderlyMeds publishes “not published” — for anything short of an explicit 50-state claim, intake is the final word.

Neither names its pharmacy publicly — the single most useful disclosure in this category, missing on both sides; ask each, in writing, before paying either.

Exit terms: Fridays — annual plan for lowest rate; not published. OrderlyMeds — none stated; not published.

Evidence: Fridays third-party reported (captured 2026-08-05); OrderlyMeds no public price (2026-08-05). Where a figure is stated-not-verified, weight it accordingly — it is a claim we could not capture on the company’s own pages.

A rule that has held across this index: disclosure predicts disclosure. Whichever of these two publishes more — pharmacies, states, exit terms — is usually the one whose invoice matches its ad.

In the full tirzepatide index these two sit at #13 and #8 of 17: between them lie 4 other programs, and the whole ladder is at cheapest tirzepatide providers. In the full semaglutide index these two sit at #7 and #4 of 20: between them lie 2 other programs, and the whole ladder is at cheapest semaglutide providers.

§ If you move

Switching between Fridays and OrderlyMeds

Prescriptions do not transfer like phone numbers: moving in either direction means completing the destination’s intake and having its prescriber write a new patient-specific prescription. The mechanics that prevent a bad month: confirm the destination serves your state and quotes your current dose in writing before cancelling anything; time the first new shipment to overlap the last old one rather than gap it; cancel the origin per its published terms (Fridays: not published; OrderlyMeds: not published) and screenshot the confirmation; and never leave a prepaid balance stranded — which is the standing argument for prepaying only after a program has already earned a few monthly cycles.

§ Verdict by situation

Which one, for whom

§ More pairings